Features of patients with advanced EGFR-mutated non-small cell lung cancer benefiting from immune checkpoint inhibitors

Overview of attention for article published in Frontiers in immunology, August 2022

Altmetric Badge

Mentioned by

twitter: 2 X users

facebook: 1 Facebook page

Citations

dimensions_citation: 6 Dimensions

Readers on

mendeley: 3 Mendeley

Summary X Facebook Dimensions citations

So far, Dimensions has found 6 publications that cite this research output.

6

The most recent citing publications are shown below. View all 6 publications that cite this research output on Dimensions.

Durable Response of Pembrolizmab for EGFR Mutation-positive Lung Adenocarcinoma with Early Progression to Osimertinib in First-line Treatment

Article in Internal Medicine (July 2024)

Case report: A lung squamous cell carcinoma patient with a rare EGFR G719X mutation and high PD-L1 expression showed a good response to anti-PD1 therapy

Article in Frontiers in Oncology (January 2024)

Sintilimab plus anlotinib as second‐ or third‐line therapy in metastatic non‐small cell lung cancer with uncommon epidermal growth factor receptor mutations: A prospective, single‐arm, phase II trial

Article in Cancer Medicine (September 2023)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.